97 related articles for article (PubMed ID: 25445)
1. Bromocriptine, lergotrile: the antiparkinsonian efficacy and the interaction with monoaminergic receptors.
Goldstein M; Lieberman A; Battista AF; Lew JY; Hata F
Pharmacology; 1978; 16 Suppl 1():143-9. PubMed ID: 25445
[TBL] [Abstract][Full Text] [Related]
2. The interactions of bromocriptine and lergotrile with dopamine and alpha-adrenergic receptors.
Lew JY; Hata F; Ohashi T; Goldstein M
J Neural Transm; 1977; 41(2-3):109-21. PubMed ID: 21229
[TBL] [Abstract][Full Text] [Related]
3. Experimental and clinical studies on bromocriptine in the Parkinsonian syndrome.
Goldstein M; Lieberman A; Battista AF; Lew JY; Matsumoto Y
Acta Endocrinol Suppl (Copenh); 1978; 216():57-66. PubMed ID: 206089
[No Abstract] [Full Text] [Related]
4. Treatment of Parkinson's disease with lergotrile mesylate.
Lieberman A; Estey E; Kupersmith M; Gopinathan G; Goldstein M
JAMA; 1977 Nov; 238(22):2380-2. PubMed ID: 335094
[TBL] [Abstract][Full Text] [Related]
5. Binding interactions of ergot alkaloids with monoaminergic receptors in the brain.
Goldstein M; Lew JY; Hata F; Lieberman A
Gerontology; 1978; 24 Suppl 1():76-85. PubMed ID: 22480
[TBL] [Abstract][Full Text] [Related]
6. Comparison between lergotrile and bromocriptine in parkinsonism.
Teychenne PF; Pfeiffer RF; Bern SM; McInturff D; Calne DB
Ann Neurol; 1978 Apr; 3(4):319-24. PubMed ID: 666273
[TBL] [Abstract][Full Text] [Related]
7. Dopaminephilic properties of ergot alkaloids.
Goldstein M; Lew JY; Nakamura S; Battista AF; Lieberman A; Fuxe K
Fed Proc; 1978 Jun; 37(8):2202-6. PubMed ID: 26607
[No Abstract] [Full Text] [Related]
8. Treatment of Parkinson's disease with dopamine agonists: a review.
Lieberman A; Neophytides A; Kupersmith M; Casson I; Durso R; Foo SH; Khayali M; Tartaro T; Goldstein M
Am J Med Sci; 1979; 278(1):65-76. PubMed ID: 39452
[TBL] [Abstract][Full Text] [Related]
9. Dopamine agonists and Parkinson's disease.
Burton K; Calne DB
Clin Neurol Neurosurg; 1984; 86(3):172-7. PubMed ID: 6091965
[TBL] [Abstract][Full Text] [Related]
10. Treatment of parkinson's disease with bromocriptine.
Lieberman A; Kupersmith M; Estey E; Goldstein M
N Engl J Med; 1976 Dec; 295(25):1400-4. PubMed ID: 989885
[TBL] [Abstract][Full Text] [Related]
11. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Henry B; Crossman AR; Brotchie JM
Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
[TBL] [Abstract][Full Text] [Related]
12. Lergotrile in Parkinson disease: further studies.
Lieberman AN; Gopinathan G; Estey E; Kupersmith M; Goodgold A; Goldstein M
Neurology; 1979 Feb; 29(2):267-72. PubMed ID: 34808
[TBL] [Abstract][Full Text] [Related]
13. A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of "de novo" Parkinson's disease patients.
Libman I; Gawel MJ; Riopelle RJ; Bouchard S
Can J Neurol Sci; 1987 Nov; 14(4):576-80. PubMed ID: 3319120
[TBL] [Abstract][Full Text] [Related]
14. Effect of adding the D1 agonist CY 208-243 to chronic bromocriptine treatment. I: Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors.
Gomez-Mancilla B; Boucher R; Gagnon C; Di Paolo T; Markstein R; Bédard PJ
Mov Disord; 1993 Apr; 8(2):144-50. PubMed ID: 8474480
[TBL] [Abstract][Full Text] [Related]
15. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P;
Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
[TBL] [Abstract][Full Text] [Related]
16. Hemiparkinsonism. A human model for studying dopaminergic supersensitivity.
Trabucchi M; Albizzati MG; Frattola L; Scarlato G
Arch Neurol; 1979 Apr; 36(4):246-8. PubMed ID: 426672
[TBL] [Abstract][Full Text] [Related]
17. Bromocriptine in Parkinson disease.
Lieberman AN; Goldstein M
Pharmacol Rev; 1985 Jun; 37(2):217-27. PubMed ID: 3901046
[TBL] [Abstract][Full Text] [Related]
18. Current status of dopamine agonists in Parkinson's disease management.
Montastruc JL; Rascol O; Senard JM
Drugs; 1993 Sep; 46(3):384-393. PubMed ID: 7693430
[TBL] [Abstract][Full Text] [Related]
19. Effects of ropinirole on various parkinsonian models in mice, rats, and cynomolgus monkeys.
Fukuzaki K; Kamenosono T; Nagata R
Pharmacol Biochem Behav; 2000 Mar; 65(3):503-8. PubMed ID: 10683491
[TBL] [Abstract][Full Text] [Related]
20. Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.
Savola JM; Hill M; Engstrom M; Merivuori H; Wurster S; McGuire SG; Fox SH; Crossman AR; Brotchie JM
Mov Disord; 2003 Aug; 18(8):872-83. PubMed ID: 12889076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
